Dog var der en uforklaret stigning i incidencen af knoglefrakturer (henholdsvis 6% mod 2, 8% i orlistat - og placebogrupperne).
However, there was an unexplained increase in the incidence of bone fractures (6% versus 2.8% in the orlistat and placebo groups, respectively).